Aleksei E. Kalinin

Aleksei E. Kalinin

Auto-generated profile, based on publicly available information

Aleksei E. Kalinin

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2020 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
GKG. G. Khakimova
G. G. Khakimova
TZT. N. Zabotina
T. N. Zabotina
ATAlexey Tryakin
Alexey Tryakin
ABA. A. Borunova
A. A. Borunova
TDT. V. Davidova
T. V. Davidova
DTDmitrii V. Tabakov
Dmitrii V. Tabakov
Objective: to study the state of cellular immunity in patients with gastric adenocarcinoma.Materials and methods. From 2017 to 2018, 45 previously untreated patients with gastric adenocarcinoma (25 with stage I–III, 20 with stage IV) received surgical / combined treatment or independent chemotherapy, respectively, at the N. N. Blokhin National Medical ResearchCenter of Oncology. Peripheral blood sampling was carried out before starting treatment. We studied the cellular composition of peripheral blood, as well as systemic immunity parameters determined by flow cytometry (CD3+CD4+; CD3+CD8+; CD4+CD8+; CD4+/CD8+; CD3–CD16+CD56+; CD3–CD19+), and their prognostic significance in relation to overall survival and progression-free survival.Results. The prognostic value of the relative indicator of platelet lymphocytic index was determined: progression-free survival in patients with a high level of platelet-lymphocytic index (208.7) was higher: 8.1 months versus 4.5 months (p = 0.0027). A favorable prognosis for overall survival was an increase in the number of CD3–CD19+ lymphocytes (hazard ratio (HR) 0.91; 95 % confidence interval (CI) 0.85–0.97; p = 0.007), and an unfavorable prognosis was an increase in the number of neutrophils (HR 1.26; 95 % CI 1.05–1.50; p = 0.012), platelet count (HR 1.01; 95 % CI 1.0–1.01; p = 0.043), as well as an increase in the number of NK cells (HR 1.04, 95 % CI 1.0–1.09; p = 0.029).Conclusion. Indicators of the cellular composition of peripheral blood, characterizing a systemic inflammatory reaction, as well as indicators of systemic immunity, can serve as additional prognostic factors for gastric cancer.

23 June 2023 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
HSH. Sun
H. Sun
SNS. N. Nered
S. N. Nered
ATAlexey Tryakin
Alexey Tryakin
EAE. V. Artamonova
E. V. Artamonova
AKA. E. Kalinin
A. E. Kalinin
ISI. S. Stilidi
I. S. Stilidi
Background. microsatellite instability (MSI) is a prognostic marker of survival in many malignant diseases and show resistance to chemotherapy at early stages of colorectal cancer and show no benefits from chemotherapy at early stages of colorectal cancer. However, the role of MSI in resectable gastric cancer (GC) remains unknown.Aim. To study the results of treatment of resectable gastric cancer with microsatellite instability.Materials and methods. The study included 286 patients with resectable gC who received treatment at the N. N. Blokhin national medical Research Center of Oncology. All patients underwent PCR testing for MSI-H in 5 markers (BAT25, BAT26, NR21, NR24, NR27). Tumor regression grades (TRG) were evaluated according to the mandard tumour regression score, including disease-free survival and overall survival.Results. MSI indicated in 27 cases (9.44 %) out of 286 resectable gastric cancer. In group patients who received only surgical treatment, 2-year disease-free survival in patients with MSI-H was 77.80 % versus 88.29 % in MSS patients (hazard ratio (HR) 1.82, 95 % confidence interval (CI) 0.37–8.82, p = 0.45), 2-year overall survival in patients with MSI-H was 88.90 % versus 95.36 % in MSS patients (HR 2.03, 95 % CI 0.20–19.8, p = 0.54). In patients who received perioperative chemotherapy, 28.57 % (4 / 14) had progression in MSI-H tumor versus 3.61 % (6 / 166) in MSS tumor (p 0.001). In group patients who received treatment combined with chemotherapy, 2-year disease-free survival in patients with MSI-H was 59.60 % versus 67.36 % (HR 1.96, CI 95 % 0.88–4.35, p = 0.09), 2-year overall survival in patients with MSI-H was 67.30 % versus 85.86 % in MSS patients (HR 1.86, 95 % CI 0.64–5.41, p = 0.25)Conclusion. MSI-H is not a favorable prognosis factor in patients with resectable GC who are treated surgically combined with chemotherapy. The prevalence of progression in patients with MSI-H-status is higher than MSS-status with perioperative chemotherapy (FLOT / FOLFIRINOX).

2 May 2024 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
AAA. Yu. Anokhin
A. Yu. Anokhin
PKP. V. Kononets
P. V. Kononets
DKD. Yu. Kanner
D. Yu. Kanner
DSD. L. Stroyakovsky
D. L. Stroyakovsky
ASA. O. Shveykin
A. O. Shveykin
ATA. S. Tyulandina
A. S. Tyulandina
Background. The established approach notably improving the therapeutic outcomes for locally advanced gastric cancer and gastroesophageal junction cancer, presently entails the amalgamation of perioperative chemotherapy aligned with the FLOT protocol and surgical intervention. However, this approach harbors limitations, as only half of the patient cohort successfully completes the entire prescribed course of drug therapy. The potential solution to this problem lies in the complete transfer of the chemotherapy volume to the preoperative period and the execution of total neoadjuvant chemotherapy with FLOT regimen.Aim. Aim is to conduct a comparative assessment of the efficacy and safety between total neoadjuvant and perioperative chemotherapy with FLOT regimen for patients with locally advanced gastric cancer and gastroesophageal junction cancer.Materials and methods. In a retrospective study we enrolled patients with histologically confirmed locally advanced gastric cancer and gastroesophageal junction cancer meeting clinical stage criteria T2–4 and N0–3, without of distant metastases, treated between 2014 and 2020 at Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” оf the Ministry of Health of the Russian Federation and Moscow City Oncologic Hospital No. 62 Department of Healthcare of Moscow. Participants in the control group underwent 8 courses of perioperative chemotherapy (4 preoperatively and 4 postoperatively), while those in the experimental group received 8 courses of total neoadjuvant chemotherapy. Both groups received drug therapy according to the FLOT protocol: 5-fluorouracil 2600 mg/m2 , intravenous drip, over 24 hours, leucovorin 200 mg/m2 , intravenous drip, oxaliplatin 85 mg/m2 , intravenous drip, docetaxel 50 mg/m2 , intravenous drip, on day 1, with a 14-day intercourse interval. The primary endpoint was one-year progression-free survival.Results. In the study included 187 patients. Participants were divided into two groups: 95 in the total neoadjuvant chemotherapy group and 92 in the perioperative chemotherapy group. The one-year progression-free survival was higher in the total neoadjuvant chemotherapy group at 79 %, compared to 68 % in the perioperative chemotherapy group (HR 0.54, 95 % confidence interval 0.32–0.9, p = 0.02). Median disease-free survival was 27.2 and 19.5 months in the neoadjuvant and perioperative chemotherapy groups, respectively. The tolerability of the entire planned drug treatment regimen was superior in the total neoadjuvant chemotherapy group, reaching 88.4 %, as opposed to 57.6 % in the perioperative chemotherapy group (p = 0.0001).Conclusion. Among patients with locally advanced gastric cancer and gastroesophageal junction cancer, the application of total neoadjuvant chemotherapy according to the FLOT protocol, administered over 8 courses, demonstrated enhanced one-year progression-free survival and improved tolerability of the entire planned treatment regimen.

15 July 2022 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
ISIvan S. Stilidi
Ivan S. Stilidi
OEOmar A. Egenov
Omar A. Egenov
SNSergey N. Nered
Sergey N. Nered
OKOleksiy E. Kalinin
Oleksiy E. Kalinin
ASAlexey S. Shevchuk
Alexey S. Shevchuk
ТСТюляндина Александра Сергеевна
Тюляндина Александра Сергеевна
Aim. To give a comparative analysis of long-term results of treatment of patients after surgical treatment in combination with systemic chemotherapy with a control group of patients who received only second-line chemotherapy without surgical treatment for recurrent ovarian cancer (OC) with lymph node (LN) involvement, as well as the search of prognostic factors that favorably affect progression-free survival (PFS) and overall survival (OS). Materials and methods. The retrospective analysis included patients under the age of 75 after surgical treatment or after only second-line chemotherapy without surgery for isolated recurrence in the LN or a combined form of recurrence of OC at Blokhin National Medical Research Center of Oncology from 2005 to 2020. All patients had previously received combined treatment for primary OC. Exclusion criteria: absence of LN involvement in the recurrence of OC, primary multiple malignant tumors, relapses of non-epithelial ovarian tumors, the presence of concomitant pathology in the decompensation phase and lack of information about the treatment received for the recurrence of OC and the date of subsequent progression, death or last observation. The primary endpoint of the study is PFS and the secondary endpoint is OS. Results. The final analysis included 214 patients, who were subsequently divided into 2 main groups: the study group consisted of patients (n=123; 57.5%) who underwent repeated cytoreduction + systemic chemotherapy, and the control group included patients (n=91; 42.5%) who received only second-line chemotherapy. In the general population of patients, the median platinum-free interval was 14.0 months. Platinum-sensitive recurrence of OC developed in 88.3% (189/214) of patients, and platinum-resistant recurrence was observed in 11.7% (25/214) of cases. In the study group, complete repeated cytoreduction was achieved in 70.7% (87/123) of patients, and incomplete in 29.3% (36/123) of patients. All 91 patients in the control group received second-line chemotherapy in the planned volume. The vast majority of patients underwent second-line platinum-containing chemotherapy 87.9% (188/214) of patients. The median follow-up was 33.0 (range 0.7174.0) months. Long-term results in the complete cytoreduction group were significantly higher median PFS and OS were 30.0 months and 87.0 months, respectively, however, in the incomplete cytoreduction group, long-term results were statistically significantly worse: median PFS and OS were 10.0 months and 29.0 months versus 12.0 months and 36.0 months, respectively, in the control group of patients. Surgical treatment in combination with chemotherapy for platinum-resistant recurrence of OC did not improve long-term results of treatment: the median PFS was the same in both groups 7.0 months, and the median OS was 24.0 months versus 21.0 months in the control group (p=0.372). Conclusion. Only complete repeated cytoreduction in combination with systemic chemotherapy leads to an improvement in long-term results of treatment compared with incomplete cytoreduction and only second-line systemic chemotherapy. Incomplete repeated cytoreduction, despite combination with systemic chemotherapy, worsens the prognosis and does not improve the results of drug therapy alone in patients with platinum-sensitive recurrence of OC. Combined treatment (surgery + chemotherapy) for platinum-resistant recurrence of OC does not improve long-term results of treatment.

31 December 2020 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
MBMarina D. Budurova
Marina D. Budurova
IFIgor A. Fainshtein
Igor A. Fainshtein
KTKirill A. Turupaev
Kirill A. Turupaev
AKAleksei E. Kalinin
Aleksei E. Kalinin
NKNikolai A. Kozlov
Nikolai A. Kozlov
This article deals with the rare clinical observation of the patient with recurrent desmoid-type fibromatosis, who have achieved long-term stability after surgical treatment. A 24-year-old patient was diagnosed with retroperitoneal tumor which size was 8.85.613 cm in 2013, infiltrating the left psoas muscle, left kidney, left common and left external iliac arteries, descending colon and sigmoid colon. The patient underwent surgery in the volume of the tumor removal, resection of the left common iliac artery and prosthetics using GORE-TEX prosthesis, left hemicolectomy, left nephrectomy at Blokhin National Medical Research Center of Oncology. The first recurrence of the tumor was detected nine months after the surgery. Due to the subsequent growth of tumor mass, located along the left external iliac artery and in the inguinal canal, the repeated surgery was performed. Then the patient had a second relapse, and underwent surgery again. The third recurrence was detected seven months after the last surgery. During the multidisciplinary discussion, according to the absence of complaints and the small size of the recurrent tumor, as well as the absence of the risk of life-threatening complications, it was decided to stop on the observation. The patient was examined once every six months there were no data concerning recurrent tumor growth. Today, the patient is alive, does not have any complaints and is able-bodied. Our clinical observation demonstrates that active surgical tactics in case of the retroperitoneal fibromatosis recurrence not always can lead to long-term progression-free survival time and several patients can stay under the observation, using Look and Stay tactic.

3 March 2020 in City Healthcare
Verified
Journal Article
Open access
PDF file
АКАлексей Евгеньевич Калинин
Алексей Евгеньевич Калинин
VGVadim Gushchin
Vadim Gushchin
ВГВадим Викторович Гущин
Вадим Викторович Гущин
The multidisciplinary team (MDT) conference has evolved as an essential instrument in the optimal management of a complex patient in the era of ever-changing medical knowledge. MDT discussions may improve the quality of diagnosis and treatment as well as provide an additional formal opportunity for collaboration among colleagues. MDT conference has become the standard of care and decision making tool in oncology. Such meetings include medical staff from all oncology-related services, and the decision is encouraged to be supported by the principles of evidence-based medicine. This paper provides an overview of the goals, pitfalls, and general recommendations for holding a productive MDT discussion.